Algernon Pharmaceuticals is working to complete an intravenous formulation (IVF) that will be used in its Phase 1 DMT study investigating the compound’s efficacy as a...
Filament Health has confirmed it has begun dosing in the first FDA-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.
A novel compound similar in structure to the psychedelic drug ibogaine, but which has no hallucinogenic effects, has been found to rapidly reverse the effects of...
Results from the largest longitudinal study investigating the practice of microdosing psilocybin for mental health, and one of the few to use a control group, have...
Mindset Pharma and Canada’s top psychiatric research hospital, CAMH, have entered into a collaboration to build the molecular profile of MSP-1014 compared to psilocybin.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
The US food and Drugs Administration (FDA) has given approval for MYCO-001 in a recent Investigational New Drug (IND) application, which will now be used in...
Ohio State University is launching The Center for Psychedelic Drug Research and Education (CPDRE).
Enosis Therapeutics has collaborated with Swinburne University and the Psychedelic Society of Belgium to carry out the study – finding that the use of virtual reality...
The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.